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Dear Sir:
Trimethylamine N-oxide (TMAO) is produced from dietary intake 
of choline, phosphatidylcholine, and L-carnitine. Recent clinical 
studies suggest a correlation between elevated plasma TMAO 
level and increased risk of cardiovascular disease and major ad-
verse cardiovascular events (MACE).1 However, reports of pa-
tients with stroke are scant and contradictory. Here, we explored 
the relationship between TMAO level and stroke outcome. 
We retrospectively analyzed data from a prospectively en-
rolled stroke registry. We included first-ever stroke patients with 
large artery atherosclerosis, cardioembolism, or lacunar infarc-
tion. Those with stoke of undetermined, or other determined 
cause were excluded. The Institutional Review Board approved 
the study and informed consent was obtained from all patients. 
Overnight fasting blood samples were collected on 1 day after 
admission. Blood was drawn by venipuncture and collected in 
EDTA at 4°C. Within 60 minutes of collection, blood samples 
were centrifuged at 4,000 rpm for 10 minutes to isolate plasma, 
then stored at –80°C until testing. Analysis of TMAO was carried 
out using liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Intra-assay imprecision of TMAO quantification 
was evaluated from five replicates measured in a single series 
and inter-assay imprecision was obtained from four different 
assays over 4 days using four different concentrations of quality 
control materials spiked with TMAO. Intra-assay coefficients of 
variation (CVs) (n=5) were 1.2% to 4.2% and inter-assay CVs 
(n=4) were 2.1% to 6.0%. It was also confirmed that repeated 
freezing and thawing (three cycles) of plasma samples, spiked 
with TMAO at two different levels, did not affect their stability; 
mean percent recovery against spiked concentrations was 98.6 
and 93.5%.
After discharge, all patients were regularly followed up at 3 
months and 1 year, and at each subsequent year. At each fol-
low-up visit, information was obtained regarding any MACE oc-
currence (recurrent stroke, myocardial infarction, or death). If a 
patient missed a visit, information was obtained from the pa-
tient or a close relative by telephone interview, using a struc-
tured questionnaire. For patients who were lost to follow-up, 
mortality data was obtained from the Korean National Statisti-
cal Office.
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Figure 1. Kaplan-Meier survival analysis for the occurrence of a major adverse 
cardiovascular event according to trimethylamine N-oxide (TMAO) level.
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Statistical analyses were performed using the R package, ver-
sion 3.1.3 (https://cran.r-project.org). Survival analyses were con-
ducted using Kaplan-Meier and Cox proportional hazard analyses. 
Observation periods were truncated at 3 years. The best cut-off 
for TMAO level was calculated using Contal and O’Quigley’s 
method, which maximizes the log-rank test statistics. Multivari-
ate analysis was performed with adjustment for parameters that 
were significant in univariate analyses (P<0.05) and blood param-
eters that were associated with TMAO concentration. 
Of 567 patients with available blood samples, 242 stroke pa-
tients of undetermined cause, and 12 patients of other deter-
mined cause were excluded. Finally, 313 patients were included 
in the study (median age 68 years: interquartile range [IQR], 57 
to 75 years; 62% men). Median TMAO level was 4.8 µmol/L 
(IQR, 2.8 to 10.0). Patients were categorized into two groups 
according to the best TMAO cut-off value for predicting MACE 
(low TMAO group: TMAO <7.5 µmol/L; high TMAO group: 
TMAO ≥7.5 µmol/L). There were more men in the high TMAO 
group than in the low TMAO group (75% vs. 55.9%, P=0.002); 
other demographic characteristics were similar. 
During follow-up, (mean 1.9±1.1 years), 72 (23%) MACE 
were reported and occurrences were significantly higher in the 
high TMAO group (31%) than in the low TMAO group (19.2%, 
P=0.031). Kaplan-Meier survival analysis revealed that MACE 
was more likely in the high TMAO group than in the low TMAO 
group (P=0.02) (Figure 1). Multivariate analysis revealed that 
TMAO was an independent predictor of MACE (hazard ratio, 
1.690; 95% confidence interval, 1.030 to 2.771), along with 
age, diabetes, initial National Institutes of Health Stroke Scale 
score, and hemoglobin level (Table 1). 
We demonstrated that TMAO level was an independent pre-
dictor of MACE in patients with first-ever stroke. This relation-
ship was observed even after adjustment for traditional risk 
factors and initial stroke severity. 
A previous study showed elevated TMAO levels are dose-de-
pendently associated with an increased risk of recurrent stroke 
and subsequent cardiovascular events in patients with first-ev-
er stroke.2 However, a case-control study of Chinese patients 
with stroke and transient ischemic attack (TIA) reported low 
TMAO plasma concentrations. The authors explained that they 
examined TMAO levels in patients who had already suffered 
from stroke or TIA. Blood TMAO levels were low compared with 
a study in a Western population, and stroke or TIA treatment 
may have reduced levels of TMAO.3 
Inconsistencies in results between studies may be related to 
differences in study methods (e.g., prospective follow-up vs. 
case-control study). As the present study had a relatively small 
sample size and possible selection bias, our results should be 
conﬁrmed in larger studies that include different ethnic groups. 
In conclusion, TMAO is a potential biomarker for the prediction 
of MACE after stroke. 
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